-+ 0.00%
-+ 0.00%
-+ 0.00%

Monte Rosa Therapeutics Advances NEK7 Program With Enhanced CNS Penetration, IND Filing Slated For 2026

Benzinga·06/10/2025 11:07:09
Listen to the news

In addition to MRT-8102, Monte Rosa is also working to advance a second-generation NEK7 program with enhanced CNS penetration with an IND submission expected in 2026. Monte Rosa retains full worldwide rights to MRT-8102 and its second-generation CNS-optimized NEK7 MGDs.